These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35248173)

  • 1. Gefapixant for chronic cough.
    Thomas D; Gibson PG
    Lancet; 2022 Mar; 399(10328):886-887. PubMed ID: 35248173
    [No Abstract]   [Full Text] [Related]  

  • 2. Gefapixant for Refractory or Unexplained Chronic Cough?
    Irwin RS; Madison JM
    JAMA; 2023 Oct; 330(14):1335-1336. PubMed ID: 37694857
    [No Abstract]   [Full Text] [Related]  

  • 3. Gefapixant Curbs Chronic Cough.
    Slomski A
    JAMA; 2022 Apr; 327(16):1539. PubMed ID: 35471515
    [No Abstract]   [Full Text] [Related]  

  • 4. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
    Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
    Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefapixant in two randomised dose-escalation studies in chronic cough.
    Smith JA; Kitt MM; Butera P; Smith SA; Li Y; Xu ZJ; Holt K; Sen S; Sher MR; Ford AP
    Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 31949115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
    Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefapixant: First Approval.
    Markham A
    Drugs; 2022 Apr; 82(6):691-695. PubMed ID: 35347635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gefapixant in the treatment of chronic coughing].
    Kühlein T; Hasford C; Nitschmann S
    Inn Med (Heidelb); 2023 Apr; 64(4):409-412. PubMed ID: 36705677
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
    Niimi A; Sagara H; Kikuchi M; Arano I; Sato A; Shirakawa M; La Rosa C; Muccino D
    Allergol Int; 2022 Oct; 71(4):498-504. PubMed ID: 35752582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
    Muccino D; Green S
    Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials.
    Chuang MH; Chen IW; Chen JY; Kang FC; Ho CN; Wu SC; Yew M; Lan KM; Hung KC
    Eur Respir Rev; 2023 Jun; 32(168):. PubMed ID: 37197770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks.
    Birring SS; Dicpinigaitis PV; Smith JA; Morice AH; McGarvey LP; Pavord ID; Nguyen AM; Schelfhout J; Li Q; Iskold B; Green SA; Philip G; Muccino DR; La Rosa C
    Am J Respir Crit Care Med; 2023 Jun; 207(11):1539-1542. PubMed ID: 36996347
    [No Abstract]   [Full Text] [Related]  

  • 13. Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
    Smith JA; Birring SS; Dicpinigaitis PV; McGarvey LP; Morice AH; Pavord ID; Satia I; Green S; Iskold B; La Rosa C; Li Q; Martin Nguyen A; Schelfhout J; Muccino D
    Lung; 2022 Aug; 200(4):423-429. PubMed ID: 35895098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery and development of gefapixant.
    Ford AP; Dillon MP; Kitt MM; Gever JR
    Auton Neurosci; 2021 Nov; 235():102859. PubMed ID: 34403981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans.
    Nussbaum JC; Hussain A; Ma B; Min KC; Chen Q; Tomek C; Iwamoto M; Stoch SA
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00924. PubMed ID: 35106949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefapixant for Chronic Cough.
    Turner RD; Smith JA; Birring SS
    JAMA; 2024 Feb; 331(6):529. PubMed ID: 38349378
    [No Abstract]   [Full Text] [Related]  

  • 17. Gefapixant for Chronic Cough-Reply.
    Kum E; Guyatt GH; Satia I
    JAMA; 2024 Feb; 331(6):530. PubMed ID: 38349375
    [No Abstract]   [Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of the P2X3-receptor antagonist gefapixant.
    Chawla A; Largajolli A; Hussain A; Kleijn H; Ait-Oudhia S; Anton J; Krishna Ananthula H; Nussbaum J; La Rosa C; Gheyas F
    CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1107-1118. PubMed ID: 37147897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coming Soon: The First-Ever Drug(s) for Refractory Chronic Cough.
    Dicpinigaitis PV
    Lung; 2021 Apr; 199(2):83-84. PubMed ID: 33825966
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
    Morice AH; Birring SS; Smith JA; McGarvey LP; Schelfhout J; Martin Nguyen A; Xu ZJ; Wu WC; Muccino DR; Sher MR
    Lung; 2021 Apr; 199(2):121-129. PubMed ID: 33825965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.